### ğŸ«  Heart Failure: SGLT2 Inhibitors in Stable HFrEF

#### âœ… True Statements
1. **Sodiumâ€“glucose cotransporterÂ 2 (SGLT2) inhibitors** such as **dapagliflozin** and **empagliflozin** reduce cardiovascular mortality and heartâ€‘failureâ€“related hospitalizations in patients with **heart failure**, irrespective of leftâ€‘ventricular ejection fraction or diabetes status.  
2. **Dapagliflozin** and **empagliflozin** are guidelineâ€‘directed standard therapy for all patients with **symptomatic heart failure with reduced ejection fraction (HFrEF)**.  
3. SGLT2 inhibitors are **contraindicated** in patients with **typeÂ 1 diabetes mellitus** or a history of **diabetic ketoacidosis**.  
4. **Dapagliflozin** should not be initiated when the **estimated glomerular filtration rate (eGFR) isÂ <30â€¯mL/min/1.73â€¯mÂ²**, and **empagliflozin** should not be initiated when **eGFR isÂ <20â€¯mL/min/1.73â€¯mÂ²**.  
5. Clinicians should use SGLT2 inhibitors cautiously in patients with **frequent urinary tract infections** or a **history of diabetic foot ulcers**.  
6. Initiation of an SGLT2 inhibitor may cause **osmotic diuresis**; therefore, clinicians should monitor **volume status**, reassess **laboratory studies**, and consider reducing **loopâ€‘diuretic dosage** after starting therapy.  
7. **Ivabradine**, a sinoatrialâ€‘node inhibitor, is indicated in symptomatic HFrEF only when the **resting heart rate remainsâ€¯>70â€¯beats/min** despite maximally tolerated **Î²â€‘blocker** therapy and is unnecessary when heart rate is **68â€¯beats/min**.  
8. **Valsartanâ€“sacubitril** (an angiotensin receptorâ€“neprilysin inhibitor) provides greater mortality benefit than **angiotensinâ€‘convertingâ€‘enzyme (ACE) inhibitors** or **angiotensin receptor blockers (ARBs)** in symptomatic HFrEF but is often limited by **hypotension** and is inappropriate in patients already hypotensive on an ARB.  
9. **Metoprolol succinate**, **carvedilol**, and **bisoprolol** are the only **Î²â€‘blockers** proven to reduce mortality in HFrEF, and no clinicalâ€‘trial evidence shows superiority of one of these agents over another.  
10. Although **carvedilol** possesses additional **Î±â€‘adrenergic blockade** and may theoretically cause more hypotension than **metoprolol succinate**, this difference has **not been proven** in clinical trials.  

#### ğŸ’¬ Extra
1. Benefits were demonstrated in large randomized trials such as **DAPAâ€‘HF** and **EMPERORâ€‘Reduced/Preserved**.  
2. SGLT2 inhibitors join **ACE inhibitor/ARB/angiotensin receptorâ€“neprilysin inhibitor**, **Î²â€‘blocker**, and **mineralocorticoid receptor antagonist** as the four foundational drug classes for HFrEF.  
3. Euglycemic ketoacidosis is the principal concern driving this contraindication.  
4. These renal thresholds reflect U.S.Â FoodÂ andÂ DrugÂ Administration labeling and major clinicalâ€‘trial inclusion criteria.  
5. Mycotic genital infections and skin ulcerations have been reported more frequently with SGLT2 inhibitor therapy.  
6. Early followâ€‘up laboratory testing typically includes **serum creatinine**, **blood urea nitrogen**, and **electrolytes** within 1â€“2Â weeks of initiation.  
7. Ivabradine primarily reduces heartâ€‘failure hospitalization when added to maximally upâ€‘titrated Î²â€‘blocker therapy.  
8. In the **PARADIGMâ€‘HF** trial, patients with **systolic blood pressureÂ <100â€¯mmâ€¯Hg** were excluded, highlighting intolerance in hypotensive individuals.  
9. Target doses for these Î²â€‘blockers are **carvedilolÂ 25â€¯mg twice daily (50â€¯mg twice daily ifâ€¯>85â€¯kg)**, **metoprolol succinateÂ 200â€¯mg daily**, and **bisoprololÂ 10â€¯mg daily**.  
10. Comparative studies have not shown clinically meaningful differences in bloodâ€‘pressure effects between carvedilol and metoprolol succinate.  

#### ğŸ”· Tags
#Cardiology #HeartFailure #HFrEF #SGLT2Inhibitor #AmbulatoryCare #PatientOver65

#### ğŸ“™ Reference
VaduganathanÂ M, DochertyÂ KF, ClaggettÂ BL, *etÂ al.* **SGLTâ€‘2 inhibitors in patients with heart failure: a comprehensive metaâ€‘analysis of five randomised controlled trials.** *Lancet*.Â 2022;400:757â€‘767. PMID:Â 36041474 doi:10.1016/S0140â€‘6736(22)01429â€‘5

#### ğŸ†” Question ID
CVMCQ24085

#### ğŸ•’ Last Updated
FebruaryÂ 2025

---

#### ğŸ“– Related Text
MKSAPÂ 19: Cardiovascular MedicineÂ â€” Heart Failure, Management of Heart Failure, Heart Failure With Reduced Ejection Fraction, Medical Therapy for Heart Failure With Reduced Ejection Fraction, SGLT Inhibitors

---

### ğŸ“˜ Related Text Derivations

#### âœ… True Statements
1. The mortality and hospitalization benefits of **sodiumâ€“glucose cotransporterÂ 2 (SGLT2) inhibitors** in heart failure appear to be **independent of osmotic diuresis**, suggesting additional cardioprotective mechanisms.  
2. The **dual sodiumâ€“glucose cotransporterÂ 1Â andÂ 2 (SGLT1/2) inhibitor sotagliflozin** is **approved for the treatment of heart failure**.  
3. No randomized trials have yet compared **dual SGLT1/2 inhibition** (for example, **sotagliflozin**) with **selective SGLT2 inhibition**; therefore, using either drug class is **considered reasonable in heartâ€‘failure management**.
4. The biguanide **metformin** provides a **survival benefit** in patients with **heart failure (HF)** but should be **discontinued** if **lactic acidosis** develops or the patient enters **cardiogenic shock**.
5. **Sulfonylurea** agents (glyburide, glipizide, glimepiride) have **no randomized controlled-trial data** evaluating outcomes in patients with **heart failure**.
6. The thiazolidinedione **pioglitazone** is **not recommended** for heart-failure patients because it is associated with an **increased risk of HF exacerbation or worsening**.
7. Observational studies suggest that **insulin therapy** may be linked to an **increased incidence or progression** of heart failure.
8. **Glucagon-like peptide-1 (GLP-1) receptor agonists** (dulaglutide, exenatide, liraglutide, semaglutide) **reduce major adverse cardiovascular events (MACE)** but show **no clear benefitâ€”or harmâ€”on heart-failure outcomes**; their use should be **cautious after a recent HF hospitalization**.
9. **Dipeptidyl peptidase-4 (DPP-4) inhibitors** (alogliptin, linagliptin, saxagliptin, sitagliptin) have **no proven cardiovascular benefit** in patients with heart failure.

#### ğŸ’¬ Extra
1. Proposed mechanisms include improved myocardial energetics, modulation of inflammatory signaling, and favorable hemodynamic effects beyond natriuresis.  
2. **Sotagliflozin** blocks **intestinal SGLT1** and **renal SGLT2**, leading to both reduced glucose absorption and enhanced glucosuria.  
3. Outcome trials such as **SCORED** and **SOLOISTâ€‘WHF** compared sotagliflozin with placebo, not with other SGLT2 inhibitors, limiting direct efficacy comparisons.
4. Metforminâ€™s benefit is largely derived from retrospective and cohort data; severe renal impairment is an additional trigger for discontinuation.
5. Available evidence is limited to observational registries; neutral or modestly adverse signals have not been confirmed in trials.
6. Fluid retention and weight gain are central mechanisms behind TZD-related HF worsening.
7. Potential mechanisms include sodium retention and adverse effects on cardiac substrate utilization.
8. The caution comes from two small post-hospitalization trials in which neutral to slightly adverse HF signals were observed.
9. Cardiovascular-outcome trials for DPP-4 inhibitors were powered for MACE but did not demonstrate benefit in HF sub-analyses.

#### ğŸ”· Tags
#HeartFailure #HFrEF #SGLT2Inhibitor #Sotagliflozin #SGLT1Inhibitor #CardioprotectiveMechanisms

---

#### ğŸ–¼ï¸ Supplemental Table

<!-- Glucose-Lowering Medications in Patients With Heart Failure -->
<table border="1" cellpadding="6" cellspacing="0" style="border-collapse:collapse; width:100%; max-width:800px;">
  <caption style="font-weight:bold; text-align:left; padding-bottom:8px;">
    Glucose-Lowering Medications in Patients With Heart Failure
  </caption>
  <thead style="background-color:#f0f0f0;">
    <tr>
      <th style="text-align:left;">Drug Class</th>
      <th style="text-align:left;">Common Drugs</th>
      <th style="text-align:left;">Considerations</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Biguanides</td>
      <td>Metformin</td>
      <td>
        Survival benefit in patients with HF<br>
        Discontinue in patients with lactic acidosis&nbsp;or cardiogenic shock
      </td>
    </tr>
    <tr>
      <td>Sulfonylureas</td>
      <td>Glyburide, Glipizide, Glimepiride</td>
      <td>No randomized data in patients with HF</td>
    </tr>
    <tr>
      <td>Thiazolidinediones</td>
      <td>Pioglitazone</td>
      <td>Not recommended because of increased risk&nbsp;/ worsening of HF</td>
    </tr>
    <tr>
      <td>Insulin</td>
      <td>&mdash;</td>
      <td>Observational studies suggest an increase in HF with insulin therapy</td>
    </tr>
    <tr>
      <td>GLP-1 receptor agonists</td>
      <td>Dulaglutide, Exenatide, Liraglutide, Semaglutide</td>
      <td>
        Reduce major adverse cardiovascular events but no effect or detriment in patients with HF<br>
        If recent HF hospitalization, use with caution (based on two small trials)
      </td>
    </tr>
    <tr>
      <td>DPP-4 inhibitors</td>
      <td>Alogliptin, Linagliptin, Saxagliptin, Sitagliptin</td>
      <td>No evidence of cardiovascular benefit</td>
    </tr>
    <tr>
      <td>SGLT2 inhibitors</td>
      <td>Canagliflozin, Dapagliflozin, Empagliflozin, Ertugliflozin</td>
      <td>
        Reduce risk for worsening HF and cardiovascular death in patients with HFrEF or HFpEF with or without type 2 diabetes mellitus<br>
        Reduce cardiovascular deaths and HFpEF hospitalizations regardless of whether diabetes is present
      </td>
    </tr>
  </tbody>
</table>
<p style="font-size:0.9em; margin-top:8px;">
  <em>
    DPP-4 = dipeptidyl peptidase-4; GLP-1 = glucagon-like peptide 1; HF = heart failure;
    HFpEF = heart failure with preserved ejection fraction; HFrEF = heart failure with
    reduced ejection fraction; SGLT2 = sodium-glucose cotransporter 2.
  </em>
</p>

---

#### ğŸ–¼ï¸ Supplemental Figure

<figure>
  <img src="Treatment of Heart Failure With Reduced Ejection Fraction (HFrEF) Stages C and D.svg" alt="Treatment of HFrEF Stages C and D">
  <figcaption>
    Treatment recommendations for patients with heart failure with reduced ejection fraction (HFrEF) are displayed. Green indicates a class 1 (strong), yellow a class 2a (moderate), and orange a class 2b (weak) recommendation. Step 1 medications may be started simultaneously at initial (low) doses recommended for HFrEF. Alternatively, these medications may be started sequentially, with sequence guided by clinical or other factors, without the need to achieve target dosing before initiating the next medication. Medication doses should be increased to target as tolerated. Although current guidelines support the use of isosorbide dinitrateâ€“hydralazine in Black patients, making management decisions on the basis of skin color is likely a flawed approach. Questions regarding the underlying studies and the appropriateness of using race to direct management are driving a reevaluation of these recommendations.<br>
    <strong>Abbreviations:</strong> ACEi = angiotensin-converting enzyme inhibitor; ARB = angiotensin receptor blocker; ARNi = angiotensin receptorâ€“neprilysin inhibitor; CRT = cardiac resynchronization therapy; GDMT = guideline-directed medical therapy; HF = heart failure; HFimpEF = heart failure with improved ejection fraction; hydral-nitrates = hydralazine and isosorbide dinitrate; ICD = implantable cardioverter-defibrillator; LBBB = left bundle branch block; LVEF = left ventricular ejection fraction; MCS = mechanical circulatory support; MRA = mineralocorticoid receptor antagonist; NSR = normal sinus rhythm; NYHA = New York Heart Association; SGLT2i = sodium-glucose cotransporter 2 inhibitor.<br>
    <em>a</em> Participation in investigational studies is appropriate for stage C, NYHA class II and III HF.<br>
    <em>Reprinted from:</em> Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure: executive summary. <em>J Am Coll Cardiol.</em> 2022. PMID: 35379504 doi:10.1016/j.jacc.2021.12.011. Â©2022, with permission from Elsevier.
  </figcaption>
</figure>